Jason Sicklick, MD, FACS

Articles

Practical Recommendations for Community Oncologists

April 28th 2025

Experts provide practical recommendations for community oncologists managing gastrointestinal stromal tumors (GIST), emphasizing optimized molecular testing and treatment sequencing decisions, and offering guidance on when and how to refer patients to specialized centers.

Next-Generation Treatment Strategies for GIST: Evaluating Combination Therapies and Mutation-Specific Approaches

April 28th 2025

Experts discuss the preliminary results of the PEAK study on the combination of bezuclastinib and sunitinib in second-line gastrointestinal stromal tumors (GIST), its potential to address heterogeneous resistance mutations, and how mutation-specific, biomarker-driven approaches in ongoing trials like INSIGHT may shift the treatment paradigm compared with traditional line-of-therapy strategies.

Managing Adverse Events With Different TKIs

April 21st 2025

Experts discuss how they approach managing adverse events with tyrosine kinase inhibitors (TKIs) like ripretinib, sunitinib, and regorafenib, highlighting notable differences in their safety profiles and how these differences influence treatment decisions.

ctDNA Biomarkers in INTRIGUE: Understanding Resistance Patterns

April 21st 2025

Experts discuss the key insights from the follow-up exploratory analysis of the INTRIGUE trial investigating circulating DNA (ctDNA) biomarkers and how mutation-specific findings may influence molecular testing before selecting a second-line agent, with practical implications for implementing a more personalized approach in clinical practice.

INTRIGUE Trial: Key Findings in Second-Line Setting

April 14th 2025

Experts discuss the key findings from the INTRIGUE trial comparing ripretinib to sunitinib in the second-line setting, focusing on efficacy endpoints like progression-free survival (PFS) and PFS on next line of therapy, and interpret the patient-reported outcome (PRO) and tolerability data reported in the study.

INVICTUS Trial: Ripretinib in Fourth-Line Setting

April 14th 2025

Experts discuss the key efficacy and safety findings from the INVICTUS trial that established ripretinib in the fourth-line setting, and how the inclusion of ripretinib has influenced their approach to managing patients with heavily pretreated gastrointestinal stromal tumors (GIST).

Post-Imatinib Progression: Decision Factors and Treatment Options

April 7th 2025

Experts discuss key factors influencing decision-making when patients with advanced gastrointestinal stromal tumors (GIST) progress on imatinib, reviewing standard second-line options, considerations for increasing imatinib dosing vs switching to a different tyrosine kinase inhibitor (TKI), and clinical or radiographic patterns that guide therapy changes or dose escalation at progression.

Monitoring Tumor Heterogeneity and Detecting Resistance

April 7th 2025

Experts discuss the tools available to monitor tumor heterogeneity and detect resistance, examining the reliability of current testing methods, differences in molecular testing for newly diagnosed metastatic patients vs those who have progressed, the role of liquid biopsy compared to traditional tissue biopsy, and how these test results inform risk assessment and clinical decision-making.

Biological Mechanisms of GIST Resistance and Tumor Heterogeneity

March 31st 2025

Experts discuss the biological mechanisms of resistance in gastrointestinal stromal tumors (GIST), differentiating between primary and secondary resistance, and explore how tumor heterogeneity evolves throughout treatment, with implications for long-term management and treatment strategies.

Optimizing TKI Selection and Sequencing Strategies in Advanced GIST Beyond First-Line Therapy

March 31st 2025

Experts discuss optimizing TKI selection and sequencing strategies for advanced gastrointestinal stromal tumors (GIST) beyond first-line therapy, focusing on the latest clinical data, molecular characterization, and insights from recent trials to guide treatment decisions.